Celcuity Inc. (CELC) Stock

Celcuity Inc. is a clinical-stage biotechnology company dedicated to advancing molecularly targeted therapies for cancer patients across the United States. Founded in 2011 and headquartered in Minneapolis, Minnesota, the company focuses on leveraging its innovative CELsignia diagnostic platform. This platform utilizes a patient's live tumor cells to pinpoint the specific abnormal cellular processes driving their cancer, enabling personalized treatment strategies.

At the forefront of Celcuity's pipeline is Gedatolisib, a promising drug candidate designed to selectively target various isoforms of PI3K and mammalian target of rapamycin (mTOR). Gedatolisib is particularly aimed at treating patients with hormone receptor positive, HER2-negative advanced or metastatic breast cancer, addressing a critical unmet need in oncology.

Celcuity Inc. is also developing the CELsignia MP test, a qualitative laboratory-developed test. This test measures signaling activity related to HER2, c-Met, and PI3K in breast and ovarian tumor cells, providing valuable insights for clinicians in optimizing treatment decisions.

In pursuit of its mission to transform cancer care, Celcuity Inc. collaborates closely with industry leaders. The company previously entered into a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib, underscoring its commitment to advancing innovative therapies through strategic partnerships. Celcuity Inc. continues to drive innovation in oncology with a focus on improving patient outcomes and quality of life through personalized medicine approaches.